Two-shots-on-goal deal gives Array best odds for $685M milestones in Genentech pact
This article was originally published in Scrip
Executive Summary
Array BioPharma CEO Robert E Conway said a new deal with long-time partner Genentech to develop Checkpoint kinase-1 (ChK-1) molecules is not only garnering his firm $28 million up front, but with a ChK-1 from both companies in the game, the "two-shots-on-goal" pact gives his biotech the best odds of achieving the $685 million in milestones on the table.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.